

Attn:File Docket No. Le A 32 70

JC14 Rec'd PCT/PTO

AUG 2001

PCT
PATENT

5.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Burchardt, et al.


Serial No.: 09/701,313

Filed: 11/28/2000

For: Monoclonal Antibody and Assay for Detecting PIIINP

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

CERTIFICATE OF MAILING UNDER 37 C.F.R § 1.8
The undersigned hereby certifies that this paper and any papers referred
to as attached is/are being deposited with the United States Postal
Service, with sufficient postage, as first class mail in an envelope
addressed to the Assistant Commissioner for Patents, Washington, D.C.
20231 on this 27th day of August, 2001.


Signature of Person Certifying

**TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))**

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449.

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The supplemental information disclosure statement transmitted herewith is being filed *before* the mailing date of the first Office action on the merits.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,




Jerrie L. Chiu
Attorney for Applicant(s)
Bayer Corporation
400 Morgan Lane
West Haven, CT 06516

Reg. No. 41,670

Telephone: (203) 812-3964

Date: August 27, 2001

SUPPLEMENTAL
INFORMATION DISCLOSURE CITATIONU.S. Department of Commerce
Patent and Trademark OfficeSerial No.
09/701,313

Group A

Filing Date
11/28/2000Atty. Docket No.
Le A 32 701

Applicant(s) Burchardt, et al.

FOREIGN PATENT DOCUMENTS

*		DOCUMENT NO.							DATE (DD/MM/YY)	COUNTRY	PRIMARY CLASS	S U B - CLASS	TRANSLATION	
		F ₃	0	3	0	4	2	9					YES	NO
									22/02/89	EP				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

R₁	Brocks, D. G., Steinert, C., Gerl, M., Knolle, J., Neubauer, H. P., and Gunzler, V., "A Radioimmunoassay for the N-terminal Propeptide of Rat Procollagen Type III", Matrix, <u>13</u> : 381-387 (1993)
R₂	Bulleid, N. J., Wilson, R., and Lees, J. F., "Type-III Procollagen Assembly in Semi-intact Cells: Chain Association, Nucleation and Triple-Helix Folding do not Require Formation of Inter-Chain Disulphide Bonds but Triple-Helix Nucleation Does Require Hydroxylation", Biochem. J., <u>317</u> : 195-202 (1996)
R₃	Colige, A., Li, S. W., Sieron, A. L., Nusgens, B. V., Prockop, D. J., and Lapierre, "cDNA Cloning and Expression of Bovine Procollagen I N-Proteinase: A New Member of the Superfamily of Zinc-Metalloproteinases with Binding Sites for Cells and Other Matrix Components", Proc. Natl. Acad. Sci. USA, <u>94</u> : 2374-2379 (March 1997)
R₄	Davies, B. H., and Madri, J. A., "An Immunohistochemical and Serum ELISA Study of Type I and III Procollagen Aminopropeptides in Primary Biliary Cirrhosis", Am. J. Pathol., <u>128</u> (2): 265-275 (1987)
R₅	Eriksen, E. F., Charles, P., Melsen, F., Mosekilde, L., Risteli, L., and Risteli, J., "Serum Markers of Type I Collagen Formation and Degradation in Metabolic Bone Disease: Correlation with Bone Histomorphometry", Journal of Bone and Mineral Research, <u>8</u> (2): 127-132 (1993)
R₆	Fleischmajer, R., Timpl, R., Tuderman, L., Raisher, L., Wiestner, M., Perlish, J. S., and Graves, P. N., "Ultrastructural Identification of Extension Aminopropeptides of Type I and III Collagens in Human Skin", Proc. Natl. Acad. Sci. USA, <u>78</u> (2): 7360-7364 (1981)
R₇	Hansen, M., Stoltengerg, M., Host, N. B., Boesby, S., Lorenzen, I., and Bentsen, K. D., "Glucocorticoids Inhibit the Synthesis Rate of Type III Collagen, but do not Affect the Hepatic Clearance of its Aminoterminal Propeptide (PIIINP)", Scand. J. Clin. Lab. Invest., <u>55</u> : 543-548 (1995)
R₈	Hayasaka, A., Koch, J., Schuppan D., Maddrey, W. C., and Hahn, E. G., "The Serum Concentrations of the Aminoterminal Propeptide of Procollagen Type III and the Hepatic Content of mRNA for the $\alpha 1$ Chain of Procollagen Type III in Carbon Tetrachloride-induced Rat Liver Fibrosis", Journal of Hepatology, <u>13</u> : 328-338 (1991)
R₉	Huse, W. D., Sastry, L., Iverson, S. A., Kang, A. S., Alting-Mees, M., Burton, D. R., Benkovic, S. J., and Lerner, R. A., "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda", Science, <u>246</u> : 1275-1281 (1989)

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUPPLEMENTAL
INFORMATION DISCLOSURE CITATION

	R₁₀	Jeffers, L. J., Coelho-Little, E., Cheinquer, H., Vargas, C., Civantos, F., Alvarez, L., Reddy, K. R., Parker, T., De Medina, M., Li, X., Hill, M., LaRue, S., and Schiff, E. R., "Procollagen-III Peptide and Chronic Viral C Hepatitis", Am. J. Gastroenterology, <u>90</u> (9): 1437-1440 (1995)
	R₁₁	Kuhn, K., Wiestner, M., Krieg, T., and Muller, P. K., "Structure and Function of the Amino Terminal Propeptide of Type I and III Collagen", Connective Tissue Research, <u>10</u> : 43-50 (1992)
	R₁₂	Lee, S.-T., Kessler, E., and Greenspan, D. S., "Analysis of Site-Directed Mutations in Human Pro- α 2(I) Collagen Which Block Cleavage by the C-Proteinase", J. Biol. Chem., <u>265</u> (35): 21992-21996 (1990)
	R₁₃	Lees, J. F., and Bulleid, N. J., "The Role of Cysteine Residues in the Folding and Association of the COOH-Terminal Propeptide of Types I and III Procollagen", J. Biol. Chem., <u>269</u> (39): 24354-24360 (1994)
	R₁₄	Moore, G. E. , Gerner, R. E., and Franklin, H. A., "Culture of Normal Leukocytes", JAMA, <u>199</u> (8): 87-92 (1967)
	R₁₅	Murawaki, Y., Ikuta, Y., Nishimura, Y., Koda, M., and Kawasaki, H., "Serum Markers for Connective Tissue Turnover in Patients with Chronic Hepatitis B and Chronic Hepatitis C: A Comparative Analysis", Journal of Hepatology, <u>23</u> : 145-152 (1995)
	R₁₆	Niemela, O., Risteli, L., Sotaniemi, E. A., and Risteli, J., "Heterogeneity of the Antigens Related to the Aminoterminal Propeptide of Type III Procollagen in Human Serum", Clinica Chimica Acta, <u>124</u> : 39-44 (1982)
	R₁₇	Peltonen, L., Halila, R., and Ryhanen, L., "Enzymes Converting Procollagens to Collagens", Journal of Cellular Biochemistry, <u>28</u> : 15-21 (1985)
	R₁₈	Plebani, M., and Burlina, A., "Biochemical Markers of Hepatic Fibrosis", Clin. Biochem., <u>24</u> : 219-239 (1991)
	R₁₉	Rohde, H., Bruckner, P., and Timpl, R., "Immunochemical Properties of the Aminopropeptide of Procollagen Type III", Eur. J. Biochem., <u>135</u> : 197-202 (1983)
	R₂₀	Rohde, H., Vargas, L., Hahn, E., Kalbfleisch, H., Brugera, M., and Timpl, R., "Radioimmunoassay for Type III Procollagen Peptide and its Application to Human Liver Disease", European Journal of Clinical Investigation, <u>9</u> : 451-459 (1979)
	R₂₁	Savolainen, E.-R., Goldberg, B., Leo, M. A., Velez, M., and Lieber, C. S., "Diagnostic Value of Serum Procollagen Peptide Measurements in Alcoholic Liver Disease", Alcoholism: Clinical and Experimental Research, <u>8</u> (4): 384-389 (1984)
	R₂₂	Schuppan, D., "Connective Tissue Polypeptides in Serum as Parameters to Monitor Antifibrotic Treatment in Hepatic Fibrogenesis", Journal of Hepatology, <u>13</u> (3): S17-S25 (1991)
	R₂₃	Scott, I. C., Halila, R., Jenkins, J. M., Mehan, S., Apostolou, S., Winqvist, R., Callen, D. F., Prockop, D. J., Peltonen, L., Kadler, K. E., "Molecular Cloning, Expression and Chromosomal Localization of a Human Gene Encoding a 33 kDa Putative Metallopeptidase (PRSM1)", Gene, <u>174</u> : 135-143 (1996)
	R₂₄	Uitto, J., Murray, L. w., Blumberg, B., and Shamban, A., "Biochemistry of Collagen Diseases", Annals of Internal Medicine, <u>105</u> : 740-756 (1986)

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.